Lead Product(s) : Albuvirtide,Lopinavir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The results of the randomized controlled, open-labelled, multicenter, non-inferiority study showed successful achievement of the primary endpoint, with a good proportion of patients on the ABT regimen with HIV RNA less than 50 copies/mL at 48 weeks.
Product Name : Aikening
Product Type : Peptide
Upfront Cash : Inapplicable
July 19, 2021
Lead Product(s) : Albuvirtide,Lopinavir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
